Literature DB >> 15613319

Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1.

Cagan Gurer1, Lionel Berthoux, Jeremy Luban.   

Abstract

The p6 domain of the human immunodeficiency virus type 1 (HIV-1) Gag polyprotein mediates virion budding from infected cells via protein-protein contacts with the class E vacuolar protein sorting factors, Tsg101 and AIP1/ALIX. Interaction with Tsg101 is strengthened by covalent attachment of monovalent ubiquitin to HIV-1 p6. To identify additional host factors that bind to HIV-1 p6, a human cDNA library was screened in the yeast two-hybrid system. HIV-1 p6 was found to interact with small ubiquitin-like modifier 1 (SUMO-1) as well as the E2 SUMO-1 transfer enzyme, Ubc9. Interaction with p6 was also detected with Daxx, a cellular protein to which SUMO-1 is sometimes covalently attached. SUMO-1 was incorporated into HIV-1 virions where it was protected within the virion membrane from digestion by exogenous protease. Of the two lysine residues in p6, lysine 27 uniquely served as a site of covalent SUMO-1 attachment. As previously reported, though, HIV-1 bearing the p6-K27R mutation replicated just like the wild type. Overproduction of SUMO-1 in HIV-1 producer cells had no apparent effect on virion release or on virion protein or RNA content. Infectivity of the resulting virions, though, was decreased, with the defect occurring after membrane fusion, at the time of viral cDNA synthesis. HIV-1 bearing the p6-K27R mutation was insensitive to SUMO-1 overexpression, suggesting that covalent attachment of SUMO-1 to p6 is detrimental to HIV-1 replication.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15613319      PMCID: PMC538558          DOI: 10.1128/JVI.79.2.910-917.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding.

Authors:  J E Garrus; U K von Schwedler; O W Pornillos; S G Morham; K H Zavitz; H E Wang; D A Wettstein; K M Stray; M Côté; R L Rich; D G Myszka; W I Sundquist
Journal:  Cell       Date:  2001-10-05       Impact factor: 41.582

2.  Structure and functional interactions of the Tsg101 UEV domain.

Authors:  Owen Pornillos; Steven L Alam; Rebecca L Rich; David G Myszka; Darrell R Davis; Wesley I Sundquist
Journal:  EMBO J       Date:  2002-05-15       Impact factor: 11.598

Review 3.  Viral late domains.

Authors:  Eric O Freed
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

4.  Structure of the Tsg101 UEV domain in complex with the PTAP motif of the HIV-1 p6 protein.

Authors:  Owen Pornillos; Steven L Alam; Darrell R Davis; Wesley I Sundquist
Journal:  Nat Struct Biol       Date:  2002-11

5.  Unconventional tethering of Ulp1 to the transport channel of the nuclear pore complex by karyopherins.

Authors:  Vikram Govind Panse; Bernhard Küster; Thomas Gerstberger; Ed Hurt
Journal:  Nat Cell Biol       Date:  2003-01       Impact factor: 28.824

6.  Enzymes of the SUMO modification pathway localize to filaments of the nuclear pore complex.

Authors:  Hong Zhang; Hisato Saitoh; Michael J Matunis
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

7.  A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes.

Authors:  Marielle Cavrois; Carlos De Noronha; Warner C Greene
Journal:  Nat Biotechnol       Date:  2002-09-30       Impact factor: 54.908

8.  AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding.

Authors:  Bettina Strack; Arianna Calistri; Stewart Craig; Elena Popova; Heinrich G Göttlinger
Journal:  Cell       Date:  2003-09-19       Impact factor: 41.582

9.  Functional replacement and positional dependence of homologous and heterologous L domains in equine infectious anemia virus replication.

Authors:  Feng Li; Chaoping Chen; Bridget A Puffer; Ronald C Montelaro
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

10.  As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity.

Authors:  Lionel Berthoux; Greg J Towers; Cagan Gurer; Paolo Salomoni; Pier Paolo Pandolfi; Jeremy Luban
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

View more
  44 in total

Review 1.  Human pathogens and the host cell SUMOylation system.

Authors:  Peter Wimmer; Sabrina Schreiner; Thomas Dobner
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15.

Authors:  Atsushi Okumura; Gengshi Lu; Ian Pitha-Rowe; Paula M Pitha
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-24       Impact factor: 11.205

Review 3.  Viral manipulation of cellular protein conjugation pathways: The SUMO lesson.

Authors:  Domenico Mattoscio; Chiara V Segré; Susanna Chiocca
Journal:  World J Virol       Date:  2013-05-12

4.  SUMO Modification Stabilizes Enterovirus 71 Polymerase 3D To Facilitate Viral Replication.

Authors:  Yan Liu; Zhenhua Zheng; Bo Shu; Jin Meng; Yuan Zhang; Caishang Zheng; Xianliang Ke; Peng Gong; Qinxue Hu; Hanzhong Wang
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

5.  Human Ubc9 contributes to production of fully infectious human immunodeficiency virus type 1 virions.

Authors:  Tareq Jaber; Christopher R Bohl; Gentry L Lewis; Charles Wood; John T West; Robert A Weldon
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

6.  The Role of Post-Translational Modifications in Targeting Protein Cargo to Extracellular Vesicles.

Authors:  Ishara Atukorala; Suresh Mathivanan
Journal:  Subcell Biochem       Date:  2021

7.  SUMO1 Modification Facilitates Avibirnavirus Replication by Stabilizing Polymerase VP1.

Authors:  Huansheng Wu; Hui Yang; Gang Ji; Tuyuan Zheng; Yina Zhang; Tingjuan Deng; Xiaojuan Zheng; Jiyong Zhou; Boli Hu
Journal:  J Virol       Date:  2019-05-01       Impact factor: 5.103

8.  Cumulative mutations of ubiquitin acceptor sites in human immunodeficiency virus type 1 gag cause a late budding defect.

Authors:  Eva Gottwein; Stefanie Jäger; Anja Habermann; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

9.  Kinesin KIF4 regulates intracellular trafficking and stability of the human immunodeficiency virus type 1 Gag polyprotein.

Authors:  Nathaniel W Martinez; Xiaoxiao Xue; Reem G Berro; Geri Kreitzer; Marilyn D Resh
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

10.  Solution structure of the equine infectious anemia virus p9 protein: a rationalization of its different ALIX binding requirements compared to the analogous HIV-p6 protein.

Authors:  Alok Sharma; Karsten Bruns; René Röder; Peter Henklein; Jörg Votteler; Victor Wray; Ulrich Schubert
Journal:  BMC Struct Biol       Date:  2009-12-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.